Puma Biotechnology Securities Litigation
HomeCase DocumentsFrequently Asked QuestionsContact UsFile Claim

Welcome to the Puma Biotechnology Securities Litigation Website

UPDATE 1/11/22: A settlement has been preliminarily approved in the above-captioned action. The Court-approved notice of the settlement can be viewed on the Case Documents tab or by clicking here. You can identify if your claim has been validated and the amount of your damages and prejudgment interest by clicking here to view the validated claims sorted by claim number, or by clicking here to view the validated claims sorted by beneficial owner. If you have submitted a validated claim, you do not need to do anything in order to receive your share of the settlement.

The deadline for any validated claimant to file an objection to the proposed settlement, including attorneys’ fees and expenses, is March 21, 2022.  For instructions on how to file an objection, click here.

In the case of HsingChing Hsu v. Puma Biotechnology, Inc., et al., No. 8:15-cv-00865, a two week trial began on January 15, 2019 in the United States District Court for the Central District of California, Southern Division. On February 4, 2019, the jury returned a verdict.

The jury found that defendants Puma and Alan H. Auerbach violated the federal securities laws by making false and misleading statements about the efficacy of Puma’s drug, neratinib, in a clinical trial and that defendants did so in knowing violation of sections 10(b) and 20(a) of the Securities Exchange Act of 1934. As a result of this fraudulent conduct, the jury determined that Puma’s stock price was artificially inflated by $4.50 per share between July 22, 2014 and May 13, 2015. You can find a copy of the jury verdict, and more information about the trial and claims process under Case Documents.

The jury verdict will result in the payment of damages, minus certain deductions described below, to eligible Class Members who file a timely and valid Proof of Claim form (submitted online or by mail) and whose claims are approved. Class Members whose claims are approved will be entitled to receive all of their damages, plus interest, less their proportionate share of any fees and expenses awarded by the Court.


Additional Information

Although the information on this website is intended to assist you, it does not replace the information contained in the Notice of Verdict in Favor of Plaintfff Class and Against Puma Biotechnology, Inc. and Alan H. Auerbach ("Notice of Verdict")  which can be found and downloaded on the Case Documents page of this website. We recommend that you read the Notice and other relevant case documents carefully.  You may also wish to read the answers to Frequently Asked Questions provided on this website. If you have not received a postcard notice and would like to confirm that you are on the mailing list for further notice mailings in this matter, please contact the Notice Administrator and request that a postcard notice be sent to you at your current mailing address.

Important Dates and Deadlines

File an Objection to the Settlement  March 21, 2022
Final Approval Hearing April 11, 2022